| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8656642 | Atherosclerosis | 2018 | 7 Pages |
Abstract
Reductions in LDL-C and other lipids with alirocumab, as well as safety and tolerability, were comparable between individuals with T2DM and with versus without MDL.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Marja-Riitta Taskinen, Stefano Del Prato, Maja Bujas-Bobanovic, Michael J. Louie, Alexia Letierce, Desmond Thompson, Helen M. Colhoun,